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a b s t r a c t
Objective: To investigate the effects of dexamethasone on brain tumor and peritumoral
edema by different sequences of magnetic resonance imaging (MRI).
Materials and methods: MRI was performed in 28 patients with brain tumor. Patients were
divided into the 3 groups based on the histological diagnosis; Group I: high-grade glial tumor,
Group II: low-grade glial tumor, and Group III: brain metastasis. The measurements of
peritumoral edema volume and apparent diffusion coefﬁcient (ADC) values were performed
while the peak areas of cerebral metabolites weremeasured by spectroscopy in groups I and
II. The changes in edema volumes, ADC values and cholin/creatine peak areas were
compared.
Results: The volume of peritumoral edemawas decreased in groups I and II, but increased in
group III after dexamethasone treatment. These changeswere not statistically signiﬁcant for
3 groups. ADC value was decreased in group I and increased in groups II and III. Changes in
ADC values were statistically signiﬁcant. Cholin/creatine peak areas were decreased after
dexamethasone in groups I and II, but these changes were also not signiﬁcant.
Conclusion: Dexamethasone has no signiﬁcant effect on the volume of peritumoral edema in
glial tumor andmetastasis. Moreover, dexamethasone increases the ﬂuidmovements in low
grade gliomas and metastases, decreases in high grade gliomas. However, more compre-
hensive clinical studies are needed to show the effects of dexamethasone on brain tumors
and peritumoral edema.
© 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.* Corresponding author at: Department of Neurosurgery, University of Health Sciences, Gulhane Education and Research Hospital, 06010
Etlik, Ankara, Turkey.
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contribute to the remaining 20%. Brain is the second most
common site for metastasis and accounted for 15% of all
metastases. Brain tumors may occur at any age, but they are
observed more common between the ages of 55 and 65 years.
Most common primary brain tumors are gliomas [1–4].
Glial tumors are the widest group of all intracranial tumors
(40–45%) [5]. Gliomasmay be solitary or multicentric [2]. These
tumors are divided into 2 groups such as low-grade glioma and
high-grade glioma based on histological examination of the
tumor specimen. Subependymal giant cell astrocytoma,
pilocytic astrocytoma, ganglioglioma, and diffuse astrocytoma
are examples of low-grade glial tumors. Anaplastic astrocyto-
ma, anaplastic oligodendroglioma and glioblastoma are the
examples of high-grade glial tumors. Although the accurate
diagnosis of gliomas is made by histological examination of
the tumor tissue, many studies attempted to reveal some
biomarkers of brain gliomas in blood and in other body ﬂuids
[3].
Metastatic tumors of the brain generate about 50% of all
supratentorial brain tumors. Breast, lung, malignant melano-
ma, and gastrointestinal tract malignancies frequentlymetas-
tasize to the brain [1,5,6].
Brain tumors are usually diagnosed with imaging techni-
ques. Currently, magnetic resonance imaging (MRI) is widely
accepted all over the world as the best imaging study for the
detection of brain tumors [5]. The characteristics of solitary
metastasis and primary gliomas are non-speciﬁc in conven-
tional MRI studies and cannot be reliably distinguished by this
examination. Contrast agent uptake of tumor cells can be seen
both of tumors and varying degrees of peritumoral edema can
be observed in MRI of patients. Themost important criteria for
histological grading of gliomas are vascular proliferation and
the degree of cellularity. Contrast-enhanced MRI scans may
provide information about the vascularity of tumor. Diffusion-
weighted and diffusion-tensor imaging may be useful to
provide information about cell density of tumor. Metastases
and high grade gliomas cause different types of peritumoral
edema in the brain. Inﬁltrative edema is observed in gliomas,
while metastases form pure vasogenic edema. Apparent
diffusion coefﬁcient (ADC)measurements are used to separate
these two types of edema in the brain [6]. Magnetic resonance
spectroscopy (MRS) is a method that distinguishes tissue
metabolites using different resonance peaks [7]. High cellu-
larity and cell-cycle secondary choline (Cho) increase are
usually seen in gliomas and N-acetyl aspartate (NAA) reduc-
tion draw attention when neurons were replaced by mass or
normal neurons take damage. Cho signals are higher in high
grade gliomas compared to low grade gliomas.
Dexamethasone is a main glucocorticoid agent that is used
to treat brain edema secondary to tumors. It was begun to use
in the early 1960s and it was previously shown that the pre-
operative dexamethasone administration reduces peritu-
moral edema and so mortality. Daily dose may range about
4–100 mg/day. It is also reported that the most powerful effect
of steroids begins within 24–72 h of treatment [8,9]. Dexa-
methasone treatment decreases brain edema without distinctabsorption effect. Although there are a lot of articles about
dexamethasone's effect on reduction of tumor size in addition
to decreasing brain edema, these statements are not widely
accepted by scientists [8,10].
The purpose of this study is to investigate the effects of
dexamethasone on the intensity of primary tumor and
peritumoral edema using advanced MRI techniques. Diffu-
sion-weighted imaging (DWI), T2-weighted-MRI andMRSwere
used for this purpose.
2. Materials and methodsAfter receiving approval from our national ethics committee
(Approval no: 25.04.2012/i B.10.4.ISM.4.06.68.49), 28 patients
were enrolled in this study. All of the patientswere over the 18-
years old and signed written consent form for this study.
Pregnant women and patients who previously underwent
brain tumor surgery had been excluded from this study.
Seventeen of 28 patients were male and 11 were female. Mean
age was 46 years (46.00  18.33) for male patients and 54.45
(54.45  13.32) years for female patients. Based on histological
diagnosis, the patients were divided into 3 groups: Group 1: High-grade tumors (n = 11)
 Group 2: Low-grade tumors (n = 10)
 Group 3: Metastatic tumors (n = 7)
The diagnosiswas high grade glial tumor in 11 patients, low
grade glial tumors in 10 patients and metastasis in 7 of 28
patients. One of the high grade tumors was gliosarcoma, while
the others were glioblastoma. One of the low grade glial
tumors was ganglioglioma, 2 were pleomorphic xantoastro-
cytomas, 2 were oligodendrogliomas and 5 were diffuse
astrocytomas. One of themetastatic tumors was breast cancer
metastasis, the others were lung cancer metastasis. Locations
of tumors were frontal, temporal, parietal and occipital lobes
respectively in order of frequency.
The main complaints of patients were headache, fatigue,
arm or leg weakness, seizure and speech disorder. Complaints
were much more in the patients with metastatic tumors and
high grade gliomas. Eleven of 28 patients had normal
neurological examination; neurological deﬁcit was present
in remaining 17 patients at different levels. Patients with
neurological deﬁcits were 94.5% of metastasis and high grade
glioma patients.
All patients with the diagnosis of brain tumor were
screened using 3T magnet (Achieva 3 T, Philips Medical
Systems, The Netherlands) preoperatively. Besides with axial
T1- and T2-weighted spin-echo imagings, T2-A ﬂuid attenuat-
ed inversion recovery (FLAIR), diffusion-weighted axial echo-
planar, and post-contrast axial, coronal and sagittal images
were also obtained. Spectroscopy sequences were also
performed. Magnetic resonance sequences which were used
in this study are shown in Table 1. Eight-channel head coil was
used during the cranial MRI. Ten milliliters of intravenous
gadoterate meglumine (Dotarem®, Guerbet) was administered
in contrast-enhanced studies. MRI's were performed pre-
treatment and 48 h after the initiation of steroid treatment. A
total of 32 mg (16 mg/day  2) dexamethasone was used as a
Table 1 – The parameters and MRI sequences that were used in this study.
Sequence TR TE Slice thickness (mm) Slice gap (mm) Flip angle Resolution
T1 536 14 4.5 6.2 90 512  512
T2 2790 80 5 6.5 150 512  512
FLAIR 11,000 120 4.5 6.2 90 512  512
Diffusion 2690 68 4.0 5.0 90 490  539
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measurement and transferred as DICOM format to a separate
computer (MacPowerBook G4, Apple, USA). Evaluations were
performed using a program that used open source DICOM
processing and visualization (OsiriX 32-bit, Pixmeo, Geneva,
Switzerland).
The following formulas were used to calculate the total
volume of peritumoral edema.1. C[(Fig._1)TD$FIG]
Fig
se
seross-sectional area of the edema of the tumor = cross-
section of tumor  (slice thickness + cross-sectional thick-
ness)2. Total volume of edema: tumor volume of ﬁrst cross-section
+ tumor volume of second cross-section + tumor volume of
n. section
During the assessment, area of the peritumoral edemawas
determined manually in T2 axial slices in order to include the
tumor. The hyper-intense area that belongs to the edema was
drawn manually in circumferential fashion for each cross-
section (Fig. 1). Volume of edema (Fig. 2) for each slice was
calculated by multiplying the sum of cross-sectional edema
area and the cross section slice thickness. The total volume of
edemawas calculated by addition of each slice volume (Fig. 3).
The areawas calculated digitally. The datawas transferred to a
database (Excel 2007, Windows 2007, Seattle, USA). Total
volume of edema and total tumor volume before and after
steroid treatment were determined by these calculations.
ADCmaps were created from diffusionweighted images by
ADC Map application on the same computer. A group of
diffusion weighted cross-section of twenty image with the
values of b = 0 and b = 1000 processed by the program and. 1 – Hand-drawn image for the tumor edema single cross
ction area and the representative image of cross-
ctional thickness.created a map. From the map, about 2 mm2 wide area created
from tumor, edemaarea and at other hemisphere symmetrical
of tumor but from normal-appearing area. This process was
repeated three times and resulted with creating an area of
interest (ROI = region of interest) with minimal ADC values
were averaged. ADC values and ratios of average were created
with Excel program as described previously. The ratio of
tumor-edema area, tumor-normal appearing area and nor-
mal-edema area was calculated separately.
Cho, Cr and NAA values generated from tumor and
peritumoral areas in MRS that were created with multi-voxel
spectroscopic images written separately and were calculated
using the same data base (Excel 2007) before and after steroid
treatment. SPSS 15.0 program (Standard version, SPSS Inc.,
USA) was used for statistical evaluation. The changes in
peritumoral edema volume before and after steroid treatment
and numerical changes in diffusion images related to the
treatment were assessed using Wilcoxon and Friedman test.
Neurological examination ﬁndings before and after dexa-
methasone treatmentwere compared usingChi-square test. p-
Value less than 0.05 was considered signiﬁcant.
3. ResultsThe mean volume of peritumoral edema before and after
steroid treatment for all patients is shown in Table 2. The
mean volume of peritumoral edema in 28 patients before the
treatment with dexamethasone was 1790.8489 mm3 (41.73–
4945.34). Mean volume of peritumoral edema after the
treatment was 1733.8743 mm3 (35.83–4890). Despite there
was a decrease in the volume of edema after treatment, it
was not statistically signiﬁcant (p = 0.56).
The mean peritumoral edema volume of 11 patients with
high grade glial tumors (Group 1) was 3014.6173 mm3 (ranged
between 1771.73 and 4945.34) before the treatment,
2959.5561 mm3 (ranged between 1896.32 and 4890.52) after
the treatment. The change in peritumoral edema volume was
not statistically signiﬁcant (p = 0.76) (Fig. 4). The mean
peritumoral edema volume of 10 cases with low grade gliomas
(Group 2)was 635.554 mm3 (ranged between 41.73 and 2014.08)
in pre-treatment period, 503.277 mm3 (ranged between 35.83
and 1678.7) after the treatment. The change in peritumoral
edema volume was not statistically signiﬁcant (p = 0.73) in
Group 2. The mean peritumoral edema volume in 7 patients
with metastases was 1518.2057 mm3 (ranged between 174.87
and 3006.93) before the treatment and 1565.7943 mm3 (ranged
between156.72 and 3062.02) after the treatment. The change in
peritumoral edema volume was not statistically signiﬁcant
(p = 0.7) in metastasis group (Table 3 and Fig. 5). The mean
volume of peritumoral edema in Group 2 was less than the
[(Fig._2)TD$FIG]
Fig. 2 – T2-weighted cross sections of each patient's tumor (A). Slice thickness multiplied by sum of cross-sectional thickness
of the space and so volume of edema can be calculated (volume of the slice = aT h) (B).
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pleomorphic xantoastrocytoma did not have signiﬁcant
peritumoral edema. Based on our data, dexamethasone
treatment does not modify signiﬁcantly the volume of
peritumoral edema in glial tumors and metastatic tumors.
DWI was performed in all cases and ADC values in the
tumor were calculated before and after dexamethasone
treatment (Table 4). The highest ADC increase was detected
in metastatic tumors (Group 3). ADC value decreased in high
grade glial tumors (Group 1). ADC increase in low grade glial
tumors (Group 2) was similar to those of metastatic tumors.
[(Fig._3)TD$FIG]Fig. 3 – Tumor edema volume was measured for each
section and calculated for total tumor volume.ADC values in peritumoral edema before and after dexameth-
asone treatment are shown in Table 5. ADC values for normal
brain parenchyma before and after dexamethasone treatment
are given in Table 6. The highest ADC increasewas observed in
Group 3 (Table 6). ADC values decreased in high grade glial
tumors. The increase in ADC values of normal brain
parenchyma in Group 2 was also close to ADC level in Group
3.
The effect of dexamethasone treatment on cerebral
metabolites in the tumoral and peritumoral area of 21 glioma
cases was also investigated in this study. Cho/Cr quantiﬁed
peak areas are shown in Table 7. In Group 1, the mean Cho/Cr
peak area was 170 mm2 (8.9–280) before the dexamethasone
treatment and 167 mm2 (8.7–267) after the treatment. Dexa-
methasone treatment did not cause a statistically signiﬁcant
change in MRS of high grade glial tumor group (p = 0.59). In
Group 2, the mean Cho/Cr peak area was 126 mm2 (7–146)
before the treatment and 125 mm2 (7.1–148) after the treat-
ment. Dexamethasone treatment did not cause a statistically
signiﬁcant change inMRS of low grade glial tumors and did not
decrease intensity of the tumoral cells at peritumoral region
( p = 0.59) (Fig. 6).
Some neurological ﬁndings such as full or partial extremity
weakness, slurred speech and consciousness were detected
before dexamethasone treatment in 17 (60.71%) of 28 patients
with the diagnosis of brain tumors. Neurological examination
was in normal ranges in 11 patients. Neurological improve-
ment was seen in 9 (52.94%) cases after the dexamethasone
treatment, but neurological ﬁndings remained unchanged in 8
patients. There was no neurological worsening in any patient
after the treatment. The effect of dexamethasone treatment
on the patient's neurological condition was statistically
signiﬁcant (p < 0.001).
4. DiscussionBrain tumor is a signiﬁcant health problemnowadays andmay
cause mortality even if treated surgically. The most common
primary brain tumor is glial tumor or glioma. Although it can
Table 2 – The changes of mean peritumoral edema volume after dexamethasone treatment in all patients.
n Mean peritumoral edema volume (mm3) Standard deviation Minimum Maximum p*
Before the dexamethasone treatment 28 1790.8489 1312.48019 41.73 4945.34 0.56
After the dexamethasone treatment 28 1733.8743 1341.95685 35.83 4890.52
* Friedman test.
[(Fig._4)TD$FIG]
Fig. 4 – 72 years-old female patient with high grade glioma (gliosarcoma). (A) T2 axial sections edema was marked. (B) A
slightly decrease in the volume of edema was observed two days after steroid treatment. (C) MRS images after the treatment
show significant increase in peak NAA. (D) In the post-treatment MRI, T1-axial cross sections showed hypointense edema
area and intense contrast enhancement in the tumor.
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more common in males than females. Most types of glial
tumors are malignant and the average life expectancy of
patients ranged from12 to 24months.Metastases are themost
common brain tumors in adults. It has been previously
reported that 25–40% of patients with systemic cancer have
brain metastasis [7,11].
MRI is the gold standard imaging technique for the
diagnosis and follow-up of brain tumors [2,3,12]. MRI was
ﬁrst described in 1946 by Bloch and Purcell. In 1980, Hawkens
revealed multiplane (multiplanar) feature of MRI and identi-ﬁed ﬁrst brain tumor with this technique. Contrast agent
(gadolinium) was used for MRI for the ﬁrst time in 1984.
Advanced MRI techniques, such as DWI, Diffusion Tensor
Imaging (DTI), perfusion MRI and MRS provide more informa-
tion beyond the anatomical knowledge [12]. Diffusion-weight-
ed sequence of MRI is described by Stejskaland and Tanner in
1965. Diffusion of H2O (water) molecules in the tissue
contributes less the quality of imaging at conventional MRI.
But it is possible to view themovement of watermolecules in a
very strong magnetic ﬁeld gradient at diffusion MRI [6]. DTI
techniques are used for differentiation and grading of gliomas,
Table 4 – The changes of ADC values in tumoral mass for each group after the dexamethasone treatment.
Group n Mean ADC value Standard deviation Minimum Maximum p*
High grade glial tumor
Before the treatment 11 608.6 259.26492 361 986 0.047
After the treatment 11 564.8 313.07395 104 922
Low grade glial tumor
Before the treatment 10 525.33 159.21474 416 708 0.041
After the treatment 10 703 141.55211 711 966
Metastasis
Before the treatment 7 321.524 115.86199 146 443 0.025
After the treatment 7 524.2 159.68625 241 628
* Friedman test.
[(Fig._5)TD$FIG]
Fig. 5 – 47-Years-old male patient with left parietal metastatic tumor. (A) Peritumoral edema area in T2 axial slice before the
steroid treatment. (B) The peritumoral edema area is increased in T2 axial slice after the steroid treatment. (C) The sagittal T2
slice of the patient shows the peritumoral edema after the steroid treatment.
Table 3 – The changes of mean peritumoral edema volume for each group after the dexamethasone treatment.
Group n Mean peritumoral edema volume (mm3) Standard deviation Minimum Maximum p*
High grade glial tumor
Before the treatment 11 3014.6173 823.36699 1771.73 4945.34 0.76
After the treatment 11 2959.5561 885.86281 1896.32 4890.52
Low grade glial tumor
Before the treatment 10 635.554 680.77382 41.73 2014.08 0.73
After the treatment 10 503.277 498.092 35.83 1678.7
Metastasis
Before the treatment 7 1518.2057 932.63096 174.87 3006.93 0.7
After the treatment 7 1565.7943 1054.80822 156.72 3062.02
* Friedman test.
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that distinguishes tissue metabolites using different reso-
nance peaks. The ﬁrst brain spectroscopy results were
obtained by Behar and colleagues at Yale University in 1983
[7]. First medical applications are made on the body ﬂuids and
secretions. MRS, perfusion MRI and DWI sequences are also in
use for this purpose. In this study, we used conventional MRI,
DWI and MRS techniques in 28 patients with glioma and
metastatic tumors and we compared the results for the effects
of dexamethasone treatment on tumor and peritumoral
edema.Metastases cause signiﬁcant peritumoral edema like high-
grade glial tumors [8]. Solitary metastasis and primary
characteristics of high-grade glial tumors are nonspeciﬁc in
conventional MRI and it is not always possible to differentiate
these tumors. Both of tumors show variable degrees of
contrast enhancement and forms peritumoral edema. T2 ﬂair,
DWI, MRS and MRI images were used in our study.
The causes of peritumoral edema are not well understood,
but it is assumed that edema is secondary to excess ﬂuid build
up in the extravascular space surrounding the tumor. Brain is
unable to remove this ﬂuid due to the disrupted blood-brain
Table 5 – The changes of ADC values in peritumoral edema for each group after the dexamethasone treatment.
Group n Mean ADC value Standard deviation Minimum Maximum p*
High grade glial tumor
Before the treatment 11 869.4 409.96073 339 1458 0.047
After the treatment 11 741.7 386.88435 84 1047
Low grade glial tumor
Before the treatment 10 370.6667 126.72937 235 486 0.041
After the treatment 10 586 182.78676 456 795
Metastasis
Before the treatment 7 386 59.37295 296 441 0.025
After the treatment 7 648.6 121.58248 469 796
* Friedman test.
Table 6 – The changes of ADC values in normal brain tissue for each group after the dexamethasone treatment.
Group n Mean ADC value Standard deviation Minimum Maximum p*
High grade glial tumor
Before the treatment 11 443.2 197.83756 174 688 0.047
After the treatment 11 380.8 178.2602 70 519
Low grade glial tumor
Before the treatment 10 326.3333 92.3598 261 432 0.041
After the treatment 10 528 170.32616 403 722
Metastasis
Before the treatment 7 195.6 21.07843 173 222 0.025
After the treatment 7 359.4 45.76899 304 428
* Friedman test.
Table 7 – The changes in Cho/Cr peak areas for high and low grade glial tumors after the dexamethasone treatment.
Group n Mean Ch/Cr peak area (mm2) Standard deviation Minimum Maximum p*
High grade glial tumor
Before the treatment 11 170 21.439 8.9 280 0.59
After the treatment 167 19.97 8.7 267
Low grade glial tumor
Before the treatment 10 126 19.26 7 146 0.62
After the treatment 125 18.22 7.1 148
* Wilcoxon test.
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treatment of peritumoral edema in the brain tumors for many
years [13,14]. According to the current knowledge, dexameth-
asone treatment reduces peritumoral edema and improves
neurological ﬁndings. Many studies have been performed on
this issue, and similar results were reported [15,16]. However,
none of these studies focused on peritumoral edema volume
and none of them used spectroscopic examinations to
investigate the correlation between the dexamethasone
treatment and clinical condition of the patients. In 1982,
Hatam et al. [17] followed three cases with serial head CT
scans. Fan et al. showed that dexamethasone inhibits glioma
cell growth. In addition, it has neuroprotective effects in brain
and reduces tumor-induced angiogenesis [18]. Andersen et al.
[19], in a series of 23 cases, investigated the effect of
dexamethasone on peritumoral edema in 1994. Andersengot MRI on the ﬁrst, 3rd, and 7th days of dexamethasone
treatment and found that peritumoral edema decreased 4.6%
at 1st day and 13.5% at 7th days of treatment [19]. Gaspar et al.
[15] published an article in 2000 and claimed that the usage of
dexamethasone 4–8 mg/day reduce peritumoral edema of
metastases radiologically and bring about a signiﬁcant
improvement in patient's clinical condition. In 2006, Sofﬁetti
et al. [20] revealed that dexamethasone treatment reduces
cerebral edema signiﬁcantly and cause clinical improvement
in 75% of patients within 24–72 h. The common point of these
studies is the use of dexamethasone reduces peritumoral
edema and intracranial pressure temporarily and improves
the patient's clinical condition [19,20]. In our study, we
examined 28 cases of glioma and metastatic tumor and
compared the volume of peritumoral edema using MRI.
Although there is a slight reduction in the volume of the
[(Fig._6)TD$FIG]
Fig. 6 – 39-Years-old female patient with low grade glioma (grade 2 astrocytoma). (A) Pre-treatment MRS examination did not
show significant difference between NAA, choline and creatine peaks for before and after treatment. (B) The same patient's
post-treatment MRS images.
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statistically signiﬁcant. Dexamethasone does not signiﬁcantly
reduce the overall volume of peritumoral edema. So, our
results are different from those of the literature.
Each of 3 groups was examined separately in order to
evaluate how dexamethasone effect groups individually. The
change of peritumoral edema volume in all of 3 groups after
the dexamethasone treatment was not statistically signiﬁcant
(p > 0.05 for all groups). Based on the data of 28 cases, we can
suggest that the dexamethasone treatment does not modify
the peritumoral edema signiﬁcantly.
Although the use of dexamethasone does not reduce the
volume of peritumoral edema, interestingly dexamethasone
treatment caused neurological improvements in 9 (52.9%) of 17
patients with neurological ﬁndings. Although our study varies
from current literature in terms of dexamethasone's effect on
peritumoral edema, its positive impact on clinical situation is
similar to those. This signiﬁcant improvement in clinical
condition may not be secondary to decrease at peritumoral
edema. Our study is one of the largest studies on this issue as a
radiological study, but more comprehensive studies with
larger series are needed.
DWI was ﬁrst used in the diagnosis of cerebral ischemia,
but it may be used for the diagnosis of traumatic brain injury,
demyelinating diseases, and determination of the tumoral
cellularity [6]. ADC values may be used for differential
diagnosis of intracranial tumors and differentiation of
peritumoral edema from tumor area [4]. There are very few
clinical studies on the use of DWI for the evaluation of
dexamethasone treatment in brain tumors. Sinha et al. [10]
published a paper on the changes of ADC value of peritumoral
edema after dexamethasone treatment in 15 patients with
brain tumor. In this study, 7 patients had glioblastoma, 4
patients hadmetastasis and 4 patients hadmeningioma. They
revealed signiﬁcant reductions in ADC values of all patients
with dexamethasone treatment after 48–72 h. They empha-
sized that dexamethasone reduces the extracellular water
movements of peritumoral brain edema and strengthens the
density of water [10]. Lu et al. [21] compared ADC changes after
dexamethasone treatment in 12 patients with glioma and 12patients with brain metastases but they did not ﬁnd statisti-
cally signiﬁcant results on the effect of dexamethasone. Bastin
et al. [22] performed the same study but they showed
signiﬁcant decrease in ADC values of just only one case of
glioblastoma patient. In our study, we measured ADC values
before and 48 h after dexamethasone treatment of 11 patients
with high grade glioma, 10 patients with low grade glioma and
7 patients with brainmetastases. ADC values of tumoralmass,
peritumoral edema, and normal cerebral tissue before and
after dexamethasone treatment were evaluated separately.
Statistically signiﬁcant changes in mean ADC values of
tumoral mass were detected in 3 groups after dexamethasone
treatment (p < 0.05 for each group). These changes in
peritumoral edema were also statistically signiﬁcant in 3
groups after dexamethasone treatment (p < 0.05 for each
group). The changes in normal brain tissue were also
statistically signiﬁcant after the treatment (p < 0.05 for each
group). Based on our results, ADC values in high grade glial
tumors decrease with dexamethasone treatment. This may be
due to rise of internal water movements of low grade glial
tumors and brainmetastases with dexamethasone treatment.
Clinical improvement in patients probably may be secondary
to the movement of water. This study is still the most
comprehensive and detailed assessment and contains dis-
crepancieswith earlier publications. There are a lot of different
results in the current literature review. DWI studies and ADC
measurements of brain tumors after dexamethasone treat-
ment are still a mysterious subject and we believe that there is
a need for investigation and evaluation in a larger tumor
groups.
There was a decrease in NAA peak at MRS, signiﬁcant
increase in Cho levels and a moderate decrease of Cr levels
(sometimesnot change) in glial tumors. NAAdecrease andCho
increase are more evident in high grade glial tumors than low
grade glial tumors [23]. In 1994, Kamada et al. [23] and in 1996
Preul et al. [24] analyzed the values of NAA, Cho, Cr, etc.
metabolites and published their results. They found a
signiﬁcant Cho peak, NAA and Cr reduction at glial tumors
in two studies [23,24]. In 1997, Chumas et al. [9] gave 12 mg/day
dexamethasone to 9 patients with brain tumors for their study
n e u r o l o g i a i n e u r o ch i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 4 9 5 – 5 0 4 503and they analyzed pre-treatment exchange value of cerebral
metabolites like NAA, Cho and Cr. They observed no signiﬁ-
cant increases or decreases of cerebral metabolites depending
on dexamethasone treatment [9]. In our study, we examined
changes in MRS ﬁndings related to the treatment with
dexamethasone in 21 patients with glioma. Patients with
brain metastases were not included in the assessment with
MRS. We examined the Cho and Cr values in tumor mass and
peritumoral area and their relative proportions with multi-
voxel two-dimensional imaging before and 48 h after dexa-
methasone treatment. The mean Cho/Cr peak area was
decreased after dexamethasone treatment in high grade
glioma group but this is not statistically signiﬁcant. There
was also decrease in mean Cho/Cr peak area after dexameth-
asone treatment in low grade glioma group and this is also not
statistically signiﬁcant. Our results with MRS are similar with
those of the previous studies.
There are 2 limitations of this study. First is the lownumber
of patient for a precise outcome for the effect of steroids on
brain tumors. Second is the limited number of tumor types
was included in this study. Only glial tumors and metastases
were analyzed for the effects of steroids. Because these tumors
are mostly treated in neurosurgery clinic, we selected these
types of tumors and performed MRI with different sequences
in order to reach a most accurate outcome.
5. ConclusionSteroid treatment improves clinical signs of glial tumors and
brain metastases. But this effect is not secondary to the
reduction of swelling around the tumor or changes in cerebral
metabolites. It is probably due to watermovements in tumoral
mass, peritumoral edema or normal brain parenchyma.
However, more detailed studies with larger series should be
done for more accurate knowledge on this topic.
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